CD44 proteolysis increases CREB phosphorylation and sustains proliferation of thyroid cancer cells

Cancer Research

Volumn 72, Issue 6, 2012, Pages 1449-1458

  De Falco, Valentina ^a   Tamburrino, Anna ^a   Ventre, Simona ^a   Castellone, Maria Domenica ^a   Malek, Mouhannad ^b   Manié, Serge N ^b   Santoro, Massimo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIN D1; GAMMA SECRETASE; HERMES ANTIGEN; METALLOPROTEINASE; PROTEIN PATCHED; PROTEIN RET; RAS PROTEIN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CARCINOMA CELL; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; THYROID CARCINOMA;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTIGENS, CD44; CARCINOMA, PAPILLARY; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIN D1; HUMANS; METALLOPROTEASES; ONCOGENES; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RET; RATS; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TRANSCRIPTION, GENETIC;

EID: 84858233251     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-3320     Document Type: Article

References (45)

1. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003;4:33-45. (Pubitemid 36077255)
2. Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 2004;4:528-39. (Pubitemid 38868622)
3. Bourguignon LY. CD44-mediated oncogenic signaling and cytoskeleton activation during mammary tumor progression. J Mammary Gland Biol Neoplasia 2001;6:287-97.
4. Strizzi L, Hardy KM, Seftor EA, Costa FF, Kirschmann DA, Seftor RE, et al. Development and cancer: at the crossroads of Nodal and Notch signaling. Cancer Res 2009;69:7131-4.
5. Okamoto I, Kawano Y, Tsuiki H, Sasaki J, Nakao M, Matsumoto M, et al. CD44 cleavage induced by a membrane-associated metalloprotease plays a critical role in tumor cell migration. Oncogene 1999;18:1435-46. (Pubitemid 29103631)
6. Kajita M, Itoh Y, Chiba T, Mori H, Okada A, Kinoh H, et al. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol 2001;153:893-904. (Pubitemid 34289231)
7. Okamoto I, Kawano Y, Murakami D, Sasayama T, Araki N, Miki T, et al. Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am J Pathol 2002;160:441-7. (Pubitemid 34160321)
8. Thorne RF, Legg JW, Isacke CM. The role of the CD44 transmembrane and cytoplasmic domains in co-ordinating adhesive and signalling events. J Cell Sci 2004;117:373-80. (Pubitemid 38181198)
9. Ciampi R, Nikiforov YE. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology 2007;148:936-41.
10. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007;28:742-62. (Pubitemid 350294294)
11. Knauf JA, Fagin JA. Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets. Curr Opin Cell Biol 2009;21:296-303.
12. Hayashi H, Ichihara M, Iwashita T, Murakami H, Shimono Y, Kawai K, et al. Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor. Oncogene 2000;19:4469-75.
13. Knauf JA, Kuroda H, Basu S, Fagin JA. RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase. Oncogene 2003;22:4406-12. (Pubitemid 36897971)
14. Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G, et al. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 2005;115:1068-81. (Pubitemid 40489412)
15. Miyagi E, Braga-Basaria M, Hardy E, Vasko V, Burman KD, Jhiang S, et al. Chronic expression of RET/PTC 3 enhances basal and insulin-stimulated PI3 kinase/AKT signaling and increases IRS-2 expression in FRTL-5 thyroid cells. Mol Carcinog 2004;41:98-107. (Pubitemid 39336759)
16. Hayashi H, Ichihara M, Iwashita T, Murakami H, Shimono Y, Kawai K, et al. Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor. Oncogene 2000;19:4469-75.
17. Pelletier L, Guillaumot P, Freche B, Luquain C, Christiansen D, Brugière S, et al. Gamma-secretase-dependent proteolysis of CD44 promotes neoplastic transformation of rat fibroblastic cells. Cancer Res 2006;66:3681-7.
18. Castellone MD, Celetti A, Guarino V, Cirafici AM, Basolo F, Giannini R, et al. Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells. Oncogene 2004;23:2188-96. (Pubitemid 38482533)
19. Guarino V, Faviana P, Salvatore G, Castellone MD, Cirafici AM, De Falco V, et al. Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness. J Clin Endocrinol Metab 2005;90:5270-8. (Pubitemid 41262285)
20. Salerno P, De Falco V, Tamburrino A, Nappi TC, Vecchio G, Schweppe RE, et al. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J Clin Endocrinol Metab 2010;95:450-5.
21. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, et al. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 2008;93:4331-41. (Pubitemid 352789529)
22. Curcio F, Ambesi-Impiombato FS, Perrella G, Coon HG. Long-term culture and functional characterization of follicular cells from adult normal human thyroids. Proc Natl Acad Sci U S A 1994;91:9004-8.
23. Fusco A, Berlingieri MT, Di Fiore PP, Portella G, Grieco M, Vecchio G. One- and two-step transformations of rat thyroid epithelial cells by retroviral oncogenes. Mol Cell Biol 1987;7:3365-70.
24. Conkright MD, Canettieri G, Screaton R, Guzman E, Miraglia L, Hogenesch JB, et al. TORCs: transducers of regulated CREB activity. Mol Cell 2003;12:413-23. (Pubitemid 37238928)
25. Albanese C, Johnson J, Watanabe G, Eklund N, Vu D, Arnold A, et al. Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem 1995;270:23589-97.
26. Marinissen MJ, Chiariello M, Tanos T, Bernard O, Narumiya S, Gutkind JS. The small GTP-binding protein RhoA regulates c-jun by a ROCK-JNK signaling axis. Mol Cell 2004;14:29-41. (Pubitemid 38469907)
27. Iavarone C, Catania A, Marinissen MJ, Visconti R, Acunzo M, Tarantino C, et al. The platelet-derived growth factor controls c-myc expression through a JNK- and AP-1-dependent signaling pathway. J Biol Chem 2003;278:50024-30. (Pubitemid 37548838)
28. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a Gsaxin-beta-catenin signaling axis. Science 2005;310:1504-10. (Pubitemid 41746348)
29. Johannessen M, Delghandi MP, Moens U. What turns CREB on? Cell Signal 2004;16:1211-27. (Pubitemid 39165450)
30. Mayr B, Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol 2001;2:599-609. (Pubitemid 33674011)
31. Boulon S, Dantonel JC, Binet V, Vié A, Blanchard JM, Hipskind RA, et al. Oct-1 potentiates CREB-driven cyclin D1 promoter activation via a phospho-CREB- and CREB binding protein-independent mechanism. Mol Cell Biol 2002;22:7769-79. (Pubitemid 35217288)
32. Chrivia JC, Kwok RP, Lamb N, Hagiwara M, Montminy MR, Goodman RH. Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 1993;365:855-9. (Pubitemid 23341031)
33. Okamoto I, Kawano Y, Murakami D, Sasayama T, Araki N, Miki T, et al. Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway. J Cell Biol 2001;155:755-62. (Pubitemid 34286228)
34. Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A, et al. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 2006;10:191-202. (Pubitemid 44311070)
35. Sharma N, Lopez DI, Nyborg JK. DNA binding and phosphorylation induce conformational alterations in the kinase-inducible domain of CREB. Implications for the mechanism of transcription function. J Biol Chem 2007;282:19872-83. (Pubitemid 47100070)
36. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004;4:937-47. (Pubitemid 39626217)
37. Feliciello A, Li Y, Avvedimento EV, Gottesman ME, Rubin CS. A-kinase anchor protein 75 increases the rate and magnitude of cAMP signaling to the nucleus. Curr Biol 1997;7:1011-4. (Pubitemid 28017082)
38. Ugi S, Imamura T, Ricketts W, Olefsky JM. Protein phosphatase 2A forms a molecular complex with Shc and regulates Shc tyrosine phosphorylation and downstream mitogenic signaling. Mol Cell Biol 2002;22:2375-87. (Pubitemid 34224640)
39. Kimura T, Van Keymeulen A, Golstein J, Fusco A, Dumont JE, Roger PP. Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr Rev 2001;22:631-56. (Pubitemid 32955247)
40. Woloshin PI, Walton KM, Rehfuss RP, Goodman RH, Cone RD. 3′,5′- cyclic adenosine monophosphate-regulated enhancer binding (CREB)4 activity is required for normal growth and differentiated phenotype in the FRTL5 thyroid follicular cell line. Mol Endocrinol 1992;6:1725-33.
41. Nguyen LQ, Kopp P, Martinson F, Stanfield K, Roth SI, Jameson JL. A dominant negative CREB (cAMP response element-binding protein) isoform inhibits thyrocyte growth, thyroid-specific gene expression, differentiation, and function. Mol Endocrinol 2000;14:1448-61.
42. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL. CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer 2008;98:756-65. (Pubitemid 351272625)
43. Todaro M, Iovino F, Eterno V,Cammareri P, Gambara G, Espina V, et al. Tumorigenic and metastatic activity of human thyroid cancer stem cells. Cancer Res 2010;70:8874-85.
44. Mesa C Jr, Mirza M, Mitsutake N, Sartor M, Medvedovic M, Tomlinson C, et al. Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Res 2006;66:6521-9. (Pubitemid 44085606)
45. Sugahara KN, Murai T, Nishinakamura H, Kawashima H, Saya H, Miyasaka M. Hyaluronan oligosaccharides induce CD44 cleavage and promote cell migration in CD44-expressing tumor cells. J Biol Chem 2003;278:32259-65. (Pubitemid 37048419)